BIOMDRIN: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
BIOMDRIN
Largest movements
- Cash +€10,573
up €10,573 (+950%), from €1,113 to €11,685
mainly Trade debts (+€9,824) and Net result for the year (+€2,799)
- Receivables within one year -€1,827
down €1,827 (-6.7%), from €27,089 to €25,261
of which Other amounts receivable: -€1,827
- Trade debts +€9,824
up €9,824 (+182%), from €5,391 to €15,214
- Tax, wage and social debts -€3,856
down €3,856 (-84.2%), from €4,581 to €725
- Profit (loss) carried forward +€2,799
up €2,799 (+19.3%), from €14,529 to €17,328
- Gross operating margin -€15,584
down €15,584 (-79.1%), from €19,713 to €4,129
- Taxes -€2,907
down €2,907 (-80.0%), from €3,632 to €725
- Depreciation -€1,131
down €1,131 (-100%), from €1,131 to €0
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €29,501 | €38,268 | +€8,767 | +29.7% |
| Current assets | 29/58 | €29,501 | €38,268 | +€8,767 | +29.7% |
| Amounts receivable within one year | 40/41 | €27,089 | €25,261 | -€1,827 | -6.7% |
| Trade receivables | 40 | €25,000 | €25,000 | = | 0.0% |
| Other amounts receivable | 41 | €2,089 | €261 | -€1,827 | -87.5% |
| Cash at bank and in hand | 54/58 | €1,113 | €11,685 | +€10,573 | +950% |
| Deferred charges and accrued income | 490/1 | €1,300 | €1,321 | +€22 | +1.7% |
| Total equity and liabilities | 10/49 | €29,501 | €38,268 | +€8,767 | +29.7% |
| Equity | 10/15 | €19,529 | €22,328 | +€2,799 | +14.3% |
| Contributions | 10/11 | €5,000 | €5,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | €14,529 | €17,328 | +€2,799 | +19.3% |
| Amounts payable | 17/49 | €9,972 | €15,939 | +€5,967 | +59.8% |
| Amounts payable within one year | 42/48 | €9,972 | €15,939 | +€5,967 | +59.8% |
| Trade debts | 44 | €5,391 | €15,214 | +€9,824 | +182% |
| Suppliers | 440/4 | €5,391 | €15,214 | +€9,824 | +182% |
| Taxes, remuneration and social security | 45 | €4,581 | €725 | -€3,856 | -84.2% |
| Taxes | 450/3 | €4,581 | €725 | -€3,856 | -84.2% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €1,131 | €0 | -€1,131 | -100% |
| Other operating charges | 640/8 | €437 | €520 | +€82 | +18.8% |
| Gross operating margin | 9900 | €19,713 | €4,129 | -€15,584 | -79.1% |
| Operating profit (loss) | 9901 | €18,145 | €3,609 | -€14,536 | -80.1% |
| Financial income | 75/76B | €25 | €0 | -€25 | -100% |
| Recurring financial income | 75 | €25 | €0 | -€25 | -100% |
| Financial charges | 65/66B | €9 | €85 | +€76 | +844% |
| Recurring financial charges | 65 | €9 | €85 | +€76 | +844% |
| Profit (loss) for the period before taxes | 9903 | €18,161 | €3,524 | -€14,637 | -80.6% |
| Income taxes | 67/77 | €3,632 | €725 | -€2,907 | -80.0% |
| Profit (loss) for the period | 9904 | €14,529 | €2,799 | -€11,730 | -80.7% |
| Profit (loss) for the period to be appropriated | 9905 | €14,529 | €2,799 | -€11,730 | -80.7% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 13 October 2026 via checked.be.